Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration

Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration

The bispecific antibody tarperprumig (ALXN1820) was developed as a treatment option for diseases involving dysregulated complement alternative pathway (AP) activity that could be administered in small volumes, either subcutaneously or intravenously. Tarperprumig incorporates a C-terminal variable do...

Full description

Saved in:
Bibliographic Details
Main Authors: Paul Tamburini, Dennis Vestergaard Pedersen, Denise Devore, Josh Cone, Rekha Patel, Todd Hunter, Fang Sun, Gregers Rom Andersen, Jeffrey Hunter
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:mAbs
Subjects:
Bispecific VHH antibody
complement alternative pathway
complement inhibition
preclinical study
properdin
tarperprumig
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2024.2415060
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items